» Articles » PMID: 21348950

Random Treatment Assignment Using Mathematical Equipoise for Comparative Effectiveness Trials

Overview
Journal Clin Transl Sci
Date 2011 Feb 26
PMID 21348950
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In controlled clinical trials, random assignment of treatment is appropriate only when there is equipoise, that is, no clear preference among treatment options. However, even when equipoise appears absent because prior trials show, on average, one treatment yields superior outcomes, random assignment still may be appropriate for some patients and circumstances. In such cases, enrollment into trials may be assisted by real-time patient-specific predictions of treatment outcomes, to determine whether there is equipoise to justify randomization. The percutaneous coronary intervention thrombolytic predictive instrument (PCI-TPI) computes probabilities of 30-day mortality for patients having ST elevation myocardial infarction (STEMI), if treated with thrombolytic therapy (TT), and if treated with PCI. We estimated uncertainty around differences in their respective predicted benefits using the estimated uncertainty of the model coefficients. Using the 2,781-patient PCI-TPI development dataset, we evaluated the distribution of predicted benefits for each patient. For three typical clinical situations, randomization was potentially warranted for 70%, 93%, and 80% of patients. Predictive models may allow real-time patient-specific determination of whether there is equipoise that justifies trial enrollment for a given patient. This approach may have utility for comparative effectiveness trials and for application of trial results to clinical practice.

Citing Articles

An example of medical device-based projection of clinical trial enrollment: Use of electrocardiographic data to identify candidates for a trial in acute coronary syndromes.

Selker H, Kwong M, Ruthazer R, Gorman S, Green G, Patchen E J Clin Transl Sci. 2019; 2(6):377-383.

PMID: 31404280 PMC: 6676436. DOI: 10.1017/cts.2019.365.


The use of patient-specific equipoise to support shared decision-making for clinical care and enrollment into clinical trials.

Selker H, Daudelin D, Ruthazer R, Kwong M, Lorenzana R, Hannon D J Clin Transl Sci. 2019; 3(1):27-36.

PMID: 31404154 PMC: 6676499. DOI: 10.1017/cts.2019.380.


Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.

Selker H, Eichler H, Stockbridge N, McElwee N, Dere W, Cohen T Clin Pharmacol Ther. 2019; 105(4):857-866.

PMID: 30610746 PMC: 6422692. DOI: 10.1002/cpt.1347.


EFFICACY-TO-EFFECTIVENESS CLINICAL TRIALS.

Selker H, Gorman S, Kaitin K Trans Am Clin Climatol Assoc. 2018; 129:279-300.

PMID: 30166723 PMC: 6116609.


A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials.

Selker H, Oye K, Eichler H, Stockbridge N, Mehta C, Kaitin K Clin Pharmacol Ther. 2013; 95(2):147-53.

PMID: 24060819 PMC: 3904553. DOI: 10.1038/clpt.2013.177.


References
1.
Thune J, Hoefsten D, Lindholm M, Mortensen L, Andersen H, Nielsen T . Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation. 2005; 112(13):2017-21. DOI: 10.1161/CIRCULATIONAHA.105.558676. View

2.
Selker H, Griffith J, Beshansky J, Schmid C, Califf R, DAgostino R . Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med. 1997; 127(7):538-56. DOI: 10.7326/0003-4819-127-7-199710010-00006. View

3.
Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

4.
Kent D, Rothwell P, Ioannidis J, Altman D, Hayward R . Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010; 11:85. PMC: 2928211. DOI: 10.1186/1745-6215-11-85. View

5.
Savvides P, Terrin N, Erban J, Selker H . Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Support Care Cancer. 2003; 11(5):313-20. DOI: 10.1007/s00520-003-0442-z. View